grant
Dual-Activity Inhibitors Targeting Aspergillus fumigatus PanK for Antifungal Therapy
NIHUS FederalResearch GrantFY2026A fumigatusA. fumigatusAcetyl CoAAcetyl Coenzyme AAddressAffectAmBAmBisomeAmphocilAmphotecAmphotercin BAmphotericin BAnabolismAnimal ModelAnimal Models and Related StudiesAntifungal TherapyAspergillosisAspergillus fumigatusAssayAzolesBioassayBiochemicalBiological AssayBlindnessCessation of lifeClinicalCoACoenzyme ACollaborationsCollectionCombined Modality TherapyContact LensesCorneaCornea TransplantationCorneal GraftingCorneal TransplantationCorneal infectionDeathDeath RateDevelopmentDrug KineticsDrug Metabolic DetoxicationDrug Metabolic DetoxificationDrugsEnzyme GeneEnzymesExhibitsEyeEye InjuriesEyeballFungal Drug ResistanceFungizoneFungus DiseasesFungus drug resistantGeneralized GrowthGoalsGrafting ProcedureGrowthHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHigh Throughput AssayHumanImmunocompromisedImmunocompromised HostImmunocompromised PatientImmunosuppressed HostImpairmentIn VitroIndividualInfectionKeratitisKeratoplastyLeadLibrariesLifeLiposomalLiposomesLung infectionsLytotoxicityMalignant Hematologic NeoplasmMaximal Tolerated DoseMaximally Tolerated DoseMaximum Tolerated DoseMedicationMetabolic Drug DetoxicationsMetabolism of Toxic AgentsMicrobial keratitisModalityModern ManMultimodal TherapyMultimodal TreatmentMycosesMysteclin-FOcular InjuryOrgan TransplantationOrgan TransplantsOutcomePantothenate kinasePathway interactionsPatient CarePatient Care DeliveryPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPb elementPharmaceutical PreparationsPharmacokineticsPhasePolyenesPopulationPredispositionPropertyResearchResistanceS-acetate Coenzyme ASiteSolidStructure-Activity RelationshipSusceptibilityTherapeuticTherapeutic FungicidesTissue GrowthToxic effectToxicitiesTraumaTreatment EfficacyTreatment outcomeTriazolesValidationVisualVoriconazoleWorkanaloganti-fungalanti-fungal agentsanti-fungal druganti-fungal drug resistanceanti-fungal drug resistantanti-fungal resistanceanti-fungal resistantbiosynthesiscare for patientscare of patientscaring for patientschemical structure functionclinical efficacyclinically approved drugclinically approved medicationclinically approved therapeutic agentcombatcombination therapycombined modality treatmentcombined treatmentcornealcorneal keratoplastycorneal transplantcytotoxicitydesigndesigningdetoxificationdevelopmentaldrug-sensitivedrug/agenteffective therapyeffective treatmentefficacy studyexperienceeye traumafungal infectionfungal infectious disease treatmentfungusfungus drug resistancefungus infectionheavy metal Pbheavy metal leadhigh throughput screeningimmunosuppressed patientimprovedin vitro activityin vivoinfections in the corneainfectious keratitisinhibitorintervention efficacymodel of animalmortality ratemouse modelmulti-modal therapymulti-modal treatmentmurine modelnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachocular traumaontogenyorgan allograftorgan graftorgan transplant patientorgan transplant recipientorgan xenograftpathogenpathwaypatient oriented outcomespharmacologicpost-transplantpost-transplantationposttransplantposttransplantationpre-clinicalpreclinicalpulmonarypulmonary infectionsresistance strainresistance to anti-fungalresistantresistant strainresistant to anti-fungalsafety studysmall molecular inhibitorsmall molecule inhibitorstatisticsstructure function relationshipsynergismtargeted agenttherapeutic efficacytherapy efficacyvalidationsvision lossvisual loss
Description preview
Research Summary
Invasive aspergillosis (IA), primarily caused by Aspergillus fumigatus, is a life-threatening infection that
predominantly affects immunocompromised individuals. Despite advancements in antifungal treatments, IA is
associated with high mortality rates; for instance, among solid organ transplant recipients, mortality rates range…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click